• Rovshan Hasanov, Elgun Samadov, Nuru Bayramov, Aytekin Ünlü, and Patrizio Petrone.
• Endocrinology Clinic, Leyla Medical Center; Baku, Azerbaijan
• Turk J Med Sci. 2020 Aug 26; 50 (5): 1262-1269.

Background/AimThis study represents the first report that evaluates the experience gathered from diagnosis, surgical treatment and outcome of insulinoma patients from Azerbaijan.Materials And MethodsWe retrospectively review of insulinoma patients for a 10-year period. Collected data included patient demographics, laboratory and imaging tests, detailed surgical reports, histopathological examination of resected specimens, and clinical follow-up.ResultsTwenty-one insulinoma patients were identified. Male patients comprised 52.4%; mean age was 44 years. Mean time to diagnosis was 14 months; 61% patients had ≥3 medical referrals due to hypoglycemia-related symptoms. Diagnosis sensitivity of CT, MRI and US was 85%, 80%, and 55%, respectively. The mean glucose, insulin, C-peptide levels were 35.7 ± 9.5 mg/dL, 33.5 ± 21.9 μU/mL, and 3.74 ± 1.88 ng/mL, respectively. Pancreatic head and tail were the most frequent tumor locations; mean tumor size was 1.5 ± 0.7 cm. No statistical association was found between the tumor size and preoperative glucose, C-peptide and insulin levels. Distal pancreatectomy and enucleation were the most common surgical procedures. Local tumor recurrence rate was 14%. There was no mortality.ConclusionsTo prevent delayed diagnoses, physicians should be familiar with the typical symptoms of these rare tumors.This work is licensed under a Creative Commons Attribution 4.0 International License.

24 keywords...

hide…